Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250033/S002

NEXUS Aortic Arch Stent Graft System

Endospan , Ltd. · Decision date Jul 24, 2026

FDA DECISIONP250033/S002

What did the FDA approve?

FDA records P250033/S002 as a supplement to PMA P250033, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 24, 2026.

FDA approval order statement

approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250033.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Jul 24, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P250033/S002
Regulatory pathway
PMA supplement
Product code
SDZ
Decision code
APPR
Decision date
Jul 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Endovascular System for Treatment of Ascending Aorta and Aortic Arch Lesions.

Product code
SDZ
FDA device class
3

For the original device and its historical approval scope, see PMA P250033. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250033 · Original PMA

    NEXUS Aortic Arch Stent Graft System

  2. P250033/S002 received

    Application receipt date recorded by FDA.

  3. P250033/S001 · Related supplement

    NEXUS Aortic Arch Stent Graft System

  4. P250033/S002 · FDA decision

    Normal 180 Day Track No User Fee

  5. P250033/S004 · Related supplement

    NEXUS Aortic Arch Stent Graft System

Timeline entries are records held by MedtechLedger for P250033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250033

Product / regulatory recordCompanyPathwayDecision dateSource
Endospan , Ltd.PMA approvalApr 2, 2026FDA
Endospan , Ltd.PMA supplementMay 20, 2026FDA
Endospan , Ltd.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Endospan , Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
105 Alta Meadows Rd., Alta, WY, 83414

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records